(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
2.50% ¥ 410.00
Live Chart Being Loaded With Signals
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 1.42M |
Średni wolumen | 3.35M |
Kapitalizacja rynkowa | 162.89B |
EPS | ¥0 ( 2024-01-31 ) |
Następna data zysków | ( ¥-323.99 ) 2024-05-13 |
Last Dividend | ¥7.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -0.940 |
ATR14 | ¥0.448 (0.11%) |
Wolumen Korelacja
Sumitomo Pharma Co., Ltd. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sumitomo Pharma Co., Ltd. Korelacja - Waluta/Towar
Sumitomo Pharma Co., Ltd. Finanse
Annual | 2022 |
Przychody: | ¥555.54B |
Zysk brutto: | ¥376.63B (67.79 %) |
EPS: | ¥-187.55 |
FY | 2022 |
Przychody: | ¥555.54B |
Zysk brutto: | ¥376.63B (67.79 %) |
EPS: | ¥-187.55 |
FY | 2022 |
Przychody: | ¥560.04B |
Zysk brutto: | ¥402.91B (71.94 %) |
EPS: | ¥102.19 |
FY | 2021 |
Przychody: | ¥515.95B |
Zysk brutto: | ¥378.18B (73.30 %) |
EPS: | ¥141.50 |
Financial Reports:
No articles found.
Sumitomo Pharma Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥14.00 (N/A) |
¥0 (N/A) |
¥7.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥4.75 | 2000-03-28 |
Last Dividend | ¥7.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 47 | -- |
Total Paid Out | ¥382.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.47 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8174.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7552.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6762.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6101.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4812.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4026.T | Ex Dividend Knight | 2023-10-30 | Semi-Annually | 0 | 0.00% | |
9982.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
3242.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
8966.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
2267.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.526 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.164 | 1.200 | -5.46 | -6.56 | [0 - 0.3] |
returnOnEquityTTM | -0.440 | 1.500 | -6.00 | -9.00 | [0.1 - 1] |
payoutRatioTTM | -0.0161 | -1.000 | -0.161 | 0.161 | [0 - 1] |
currentRatioTTM | 0.627 | 0.800 | -1.864 | -1.491 | [1 - 3] |
quickRatioTTM | 0.333 | 0.800 | -2.75 | -2.20 | [0.8 - 2.5] |
cashRatioTTM | 0.0866 | 1.500 | -0.630 | -0.945 | [0.2 - 2] |
debtRatioTTM | 0.389 | -1.500 | 3.52 | -5.29 | [0 - 0.6] |
interestCoverageTTM | -8.87 | 1.000 | -4.40 | -4.40 | [3 - 30] |
operatingCashFlowPerShareTTM | -693.01 | 2.00 | -10.00 | -10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -728.72 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 1.199 | -1.500 | 5.20 | -7.81 | [0 - 2.5] |
grossProfitMarginTTM | 0.599 | 1.000 | 3.34 | 3.34 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.536 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.669 | 1.000 | -4.83 | -4.83 | [0.2 - 2] |
assetTurnoverTTM | 0.312 | 0.800 | -1.256 | -1.005 | [0.5 - 2] |
Total Score | -5.81 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.938 | 1.000 | -0.196 | 0 | [1 - 100] |
returnOnEquityTTM | -0.440 | 2.50 | -3.86 | -9.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -728.72 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -693.01 | 2.00 | -10.00 | -10.00 | [0 - 30] |
payoutRatioTTM | -0.0161 | 1.500 | -0.161 | 0.161 | [0 - 1] |
pegRatioTTM | -2.71 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.834 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -5.01 |
Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej